- Home
- JRS vs VOR Comparison
JRS vs VOR Comparison
Compare JRS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- VOR
- Stock Information
- Founded
- JRS 2001
- VOR 2015
- Country
- JRS United States
- VOR United States
- Employees
- JRS N/A
- VOR N/A
- Industry
- JRS Finance/Investors Services
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- VOR Health Care
- Exchange
- JRS Nasdaq
- VOR Nasdaq
- Market Cap
- JRS 224.5M
- VOR 202.4M
- IPO Year
- JRS N/A
- VOR 2021
- Fundamental
- Price
- JRS $7.58
- VOR $2.10
- Analyst Decision
- JRS
- VOR Buy
- Analyst Count
- JRS 0
- VOR 7
- Target Price
- JRS N/A
- VOR $3.77
- AVG Volume (30 Days)
- JRS 86.6K
- VOR 11.3M
- Earning Date
- JRS 01-01-0001
- VOR 08-11-2025
- Dividend Yield
- JRS 8.87%
- VOR N/A
- EPS Growth
- JRS N/A
- VOR N/A
- EPS
- JRS N/A
- VOR N/A
- Revenue
- JRS N/A
- VOR N/A
- Revenue This Year
- JRS N/A
- VOR N/A
- Revenue Next Year
- JRS N/A
- VOR N/A
- P/E Ratio
- JRS N/A
- VOR N/A
- Revenue Growth
- JRS N/A
- VOR N/A
- 52 Week Low
- JRS $5.95
- VOR $0.13
- 52 Week High
- JRS $8.00
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- JRS 34.42
- VOR 56.27
- Support Level
- JRS $7.80
- VOR $2.03
- Resistance Level
- JRS $7.88
- VOR $2.38
- Average True Range (ATR)
- JRS 0.12
- VOR 0.27
- MACD
- JRS -0.03
- VOR -0.08
- Stochastic Oscillator
- JRS 9.30
- VOR 24.66
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.